<?xml version="1.0" encoding="UTF-8"?>
<p>Augmentation therapy with alpha-1 antitrypsin slows disease progression (
 <xref rid="B3" ref-type="bibr">Chapman et al., 2015</xref>; 
 <xref rid="B7" ref-type="bibr">McElvaney et al., 2017</xref>) and discontinuation of treatment was associated with poor health outcomes, increased number of exacerbations and hospitalizations (
 <xref rid="B1" ref-type="bibr">Alkins and O'Malley, 2000</xref>; 
 <xref rid="B9" ref-type="bibr">Sclar et al., 2012</xref>; 
 <xref rid="B8" ref-type="bibr">McElvaney et al., 2020</xref>). Some studies concluded that augmentation therapy is a cost-effective strategy for managing AATD patients with COPD (
 <xref rid="B1" ref-type="bibr">Alkins and O'Malley, 2000</xref>; 
 <xref rid="B9" ref-type="bibr">Sclar et al., 2012</xref>). An observational study among Spanish patients also showed that these patients experienced a significant decrease in hospitalization costs and incidence of exacerbations following the start of augmentation therapy (
 <xref rid="B2" ref-type="bibr">Barros-Tiz√≥n et al., 2012</xref>).
</p>
